Compare
Lantern Pharma Inc. vs Decoy Therapeutics Inc. vs MetaVia Inc. vs NewcelX Ltd.
| Latest fiscal year | Lantern Pharma Inc. LTRN | Decoy Therapeutics Inc. DCOY | MetaVia Inc. MTVA | NewcelX Ltd. NCEL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$17.12M | -$12.52M | -$12.97M | -$8.30M |
| EPS (Diluted) | -$1.57 | -$129.10 | -$7.35 | $2.16 |
| Operating cash flow | -$15.68M | -$4.83M | -$15.70M | -$2.77M |
| Free cash flow | -$15.68M | -$5.40M | -$15.70M | -$2.77M |
| Cash & equivalents | $4.42M | $10.71M | $10.28M | $2.20M |
| Total assets | $11.04M | $11.06M | $11.12M | $11.45M |
| Total liabilities | $4.50M | $5.17M | $5.79M | $4.20M |
| Shareholders' equity | $6.53M | $5.89M | $5.33M | $7.25M |
| Return on year-end equity | -262.0% | -212.6% | -243.3% | -114.5% |
| Shares outstanding | 11.25M | n/a | 2.31M | 4.80M |
Revenue, most recent five fiscal years
| Fiscal year | Lantern Pharma Inc. | Decoy Therapeutics Inc. | MetaVia Inc. | NewcelX Ltd. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2022-12-31 | n/a | n/a |
| 1 year earlier | n/a | $1.84M Ended 2021-12-31 | n/a | n/a |
| 2 years earlier | n/a | $5.23M Ended 2020-12-31 | n/a | n/a |
| 3 years earlier | n/a | $3.47M Ended 2019-12-31 | n/a | n/a |
| 4 years earlier | n/a | $1.95M Ended 2018-12-31 | n/a | n/a |